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Background: A nosocomial outbreak of Acinetobacter baumannii (AB) infections occurred among intensive care
units (ICU) (surgery, medical, cardiovascular surgery, coronary unit) of Recep Tayyip Erdogan University Medical
School (Rize, Turkey) between January 2011 and May 2012. The identification of isolates and clonal relation among
them were investigated by molecular techniques.
Methods: A total of 109 AB isolates were obtained from 64 clinical materials from 54 ICU patients and 3 from
the hands of healthcare workers (HCWs) of 42 environmental samples. The isolates were identified by 16S rDNA
sequencing and OXA- specific PCR. The clonal relation between isolates was investigated by PFGE methods using
ApaI restriction enzyme.
Results: All isolates were determined as AB by 16S rDNA sequencing and OXA-spesific PCR. While the blaOXA-51-like
gene was amplified in all isolates, the blaOXA-23-like gene was amplified from 103 isolates. The PFGE pattern generated
9 pulsotypes and showed that the isolates from patients, HCWs, and the environment were genetically related. In 7 of
these pulsotypes, there were 107 strains (98%) showing similar PFGE profiles that cannot be distinguished from each
other, ranging from 2 to 53. The remaining 2 pulsotypes were comprised of strains closely associated with the main
cluster. Two major groups were discovered with similarity coefficient of 85% and above. The first group consisted of 97
strains that are similar to each other at 92.7% rate, and the second group consisted of 12 strains that are 100% identical.
Conclusions: The common utilization of the blood gas device among ICU was the reason for the contamination.
AB strains can remain stable for a long period of time, although due to the disinfection procedures applied in
hospitals, there is a small chance that the same clone might reappear and cause another epidemic. For that reason, the
resistance profiles of the strains must be continuously followed with amplification-based methods, and these methods
should be used to support the PFGE method in the short term.
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Acinetobacter baumannii (AB), a non-fermentative, gram-
negative bacteria, is an opportunist agent commonly exist-
ing in nature [1,2]. It can be alive for days on a lifeless
surface and cause nosocomial infections in hospital
environments [3-5]. Acinetobacter spp may especially
cause ventilator-related pneumoniae and bacteriemia,* Correspondence: ayseace25@hotmail.com
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and wound infections [6,7]. AB strains that are frequently
isolated from nosocomial infections are resistant to
many agents including carbapenems [8-10]. Recently,
AB epidemics have been reported that are resistant to
all antibiotics except polymixines, and this situation
has led to a search for new drug options [10-12]. The
problems in the production of any antibiotic drug and
the resistant nature of the bacteria have caused a need for
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cific clones resistant to carbapenem have been persistent,
and there is a possibility of clonal expansion throughout
the world [13-17].
This study assessed the epidemic level of AB found in
intensive care units (ICU) (surgery, medical, cardiovascular
surgery, coronary care unit) from Recep Tayyip Erdogan
University Hospital (RTEUH) between January 2011 and
May 2012. It also evaluated its source, probable avenues
of contamination, and its clonal relations to determine
the effective control measurements for AB in RTEUH,
which is a public hospital with 450 beds. Located in the
east Black Sea region of Turkey, the hospital services
around half a million people. There are 9 beds in the
surgery intensive care unit (SICU); 8 beds in the medical
intensive care unit (MICU); 6 beds in the cardiovascular
surgery intensive care unit (CVSICU), in which all of them
have ventilator equipment; and 16 beds in the coronary
care unit (CICU), in which two of them have isolation
rooms with ventilatory equipment. In a one and a half year
period (January 2011 through May 2012), the number of
patients hospitalized for RTEUH was 51,828, of which
1,132 were admitted to intensive care units.Methods
Bacterial isolates
One hundred and nine AB strains were collected from
RTEUH between January 2011 and May 2012. Samples
were obtained from each ICU separately, from intravenous
(IV) catheters, medication solutions, IV solutions, ICU
environments, surfaces of the study areas, ventilators,
laryngoscopy knives, incubators, taps, sinks, drug con-
tainers, IV drop supporters, monitors, tables, feeding
pumps, patients’ charts or fields, mechanic ventilation
(MV) equipment, intubation tubes, intubation knives,
resuscitation equipment, resuscitation cars, and blood
gas devices located in the corridor, comprising 8 square
meters between surgery and the CVSICU. At the same
time, samples were collected from ICU workers’ hands by
a direct cultivation process. These hand samples of health
workers were collected immediately after direct contact
with a patient who required an emergency procedure.Evaluating the epidemic
Based on data obtained by Hospital Infection Control
Committee Team reports in January 2012, it was discov-
ered that there was an AB epidemic in all ICUs during
the last three months of year and simultaneously the
preventive intervention had been started to get under
control the epidemic. During the investigation, all suspect
health procedures and infection control applications were
analyzed. For the epidemiologic side of the investigation,
cultures of the environment, equipment, hands of healthworkers, and other aforementioned items were evaluated.
Because of the probability that the same strain caused the
epidemic in the other four ICUs, the focus was directed
to common contamination sources, common areas, equip-
ment, transfer conditions, and personnel factors. The AB
epidemic was not previously observed in the CVSICU
previously and it was caused in the operating room.
The blood gas instrument, frequently used during the
cardiovascular surgery and commonly used temporarily
by the SICU, CVSICU, CICU, and MICU, was examined
to reach the source of contamination. At the beginning
of May, a second investigation began because the cases
continued to appear. From mid-January onward, on the
first day a patient was admitted to any ICU and then
weekly thereafter, cultures of the pharynx, axilla, and
rectum of each patient were scanned.Identification of A. baumannii isolates
The samples obtained were cultured on bloody agar and
EMB agar, and conventional methods plus a VITEK-2
Compact Automated System (bioMerieux, Marcy-l’Etoile,
France) were used for bacterial identification and anti-
biograms. The antibiotic susceptibility of the isolated
strains was determined by the Kirby Bauer disk diffusion
method (CLSI 2010) [18]. Ampicillin-sulbactam (10/10 μg),
piperaciline-tazobactam 100/10 μg, cefepime (30 μg),
ceftazidime (30 μg), imipenem (10 μg), meropenem
(10 μg), gentamicin (10 μg), amikacin (30 μg), tobrami-
cin (10 μg), netilmicin (30 μg), trimethoprim/sulfameth-
oxazole (1.25 μg/23 μg), ciprofloxacin (5 μg), colistin
(10 μg), and tigecycline (15 μg) antibiotic disks (Oxoid,
UK) were used. P.aeruginosa ATCC 27853 was studied as
the quality control strain. For colistin, the interpretive
criteria of Galani et al. [19], and for tigecycline, the inter-
pretive criteria of Jones et al. [20], were applied. The
imipenem-resistant strains were detected by the disk
diffusion method and confirmed by the imipenem E-test
(Oxoid M.I.C Evaluator, UK).16S rRNA gene sequencing of A. baumannii
Molecular identification of the isolates was performed by
a 16S rRNA gene sequencing. AB isolates were grown in
Luria Broth at 37°C overnight and collected by centrifuge
at 13,000 rpm for 5 min. A pellet was suspended in
300 μl of distilled water and boiled for 10 min. It was
then centrifuged again at 13,000 rpm for 20 min. The
supernatant was transferred into a new tube and used
as a DNA template. The oligonucleotide primers of 27 F
(5′-AGAGTTTGATCMTGGCTCAG-3 as forward) and
1492R (5′-GGYTACCTTGTTACGACTT-3′ as reverse)
(Macrogen) were used to amplify the 16S rRNA gene
for isolate. The polymerase chain reaction (PCR) con-
tained 10 μl of 5X Taq DNA polymerase reaction buffer
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opposing primers, 1.5 U of GoTaqFlexi Polymerase
(Promega, USA), 3 mM of MgClμ, and 5 μl genomic
DNA in a final volume of 50 μl reaction volume. The
PCR was performed under the following conditions:
2 min initial denaturation at 94°C; 35 cycles of denaturation
(45 s at 94°C), annealing (60 s at 55°C), and extension
(60 s at 72°C); and a final extension at 72°C for 10 min.
Finally, the PCR product was analyzed by electrophoresis
in 1% agarose gel and then visualized under UV light by
staining with ethidium bromide. The PCR product was
sent to Macrogen (The Netherlands) for sequencing. The
same primer pairs were used for sequencing. The obtained
sequence was analyzed by BLAST searches using the
NCBI GenBank database [21].
Multiplex PCR for detection of blaOXA genes
Multiplex PCR was used for detecting blaOXA-51-like,
blaOXA-23-like, blaOXA-40-like, and blaOXA-58-like genes
[22]; and blaOXA-48 [23] was investigated separately. The
primers used in obtaining the PCR amplifications and
the expected size of those PCR amplifications are shown
in Table 1. DNA extracts were conducted using a boiling
method. PCRs were performed in a final volume of
50 μL and included 5 μL of genomic DNA, 20 pM of
each primer, 10 μL reaction buffer (Promega), 3 μL
25 mM MgCl2, 200 μM of each dNTPs, and 1.5 U of
Taq Polymerase (Promega). PCR amplification condi-
tions were as follows: initial denaturation at 94°C for
3 min followed by 30 cycles of 25 s at 94°C, 40 s at 52°C
and 50 s at 72°C, with a final extension of 5 min at 72°C.
All PCR results were analyzed on 1% agarose containing
0.5 mg/L ethidium bromide and subsequently visualized
under UV light.
Pulsed-field gel electrophoresis (PFGE) analysis
The clonal relation among AB strains were analyzed
according to the suggested protocol, by Durmaz et al. [24],Table 1 The primer pairs used for amplification of
OXA genes




















R:GAGCACTTCTTTTGTGATGGCusing the ApaI restriction enzyme for the PFGE method.
After PFGE, a dendogram analysis of band profiles was
carried out using the Bionumerics (Applied Maths, Inc.,
Belgium, 6.01 version) program. In the evaluation of the
clonal relations, the criteria suggested by Tenover et al.
was used [25].
Results
One hundred and nine AB isolates were collected from
64 clinical materials (3 of bronchoalveloar lavage, 2 of
urine, 8 of blood, 2 of catheter, 1 of gaita, 1 of vagina, 4 of
wound, 43 of tracheal aspirate cultures) from a total of 54
patients, 42 samples from a total of 233 environmental
samples, and 3 from workers’ hands from a total of 18
personnel. Fifty AB isolates, obtained from 64 clinical
samples from all four ICUs, were the cause of the hospital
infection (35 of them were ventilator-related pneumoniae,
10 of them were bacteremia, 2 of them were urinary tract
infections, and 3 of them were surgical area infections),
and the rest (14) were due to colonization (Figure 1). All
isolates were confirmed by biochemical characterization
and 16S rDNA sequencing analysis. A hospital infection
diagnosis was carried out using Centers for Disease Con-
trol and Prevention (CDC) criteria. Infection speed and
invasive tool use rates were calculated in accordance with
the requirements of the National Hospital Infections
Surveillance Web (NHISW). Nineteen of the 54 patients
infected with AB died.
All isolates were resistant to carbapenems and multiple
antibiotics but sensitive to colistin and tigecycline. The
highest resistance rate was found for ciprofloxacin, fol-
lowed by piperacillin-tazobactam, with a 97.2% rate, and
cefepime (Table 2). Imipenem and meropenem resistance
were found at 91.9% and 93.5%, respectively. An E-test
was carried out on all imipenem resistant strains; all were
found as ≥ 32 μg/mL. blaOXA-51-like was found as positive
in all 109 strains, whereas blaOXA-23-like was positive in
103 strains, while blaOXA-24-like, blaOXA-48-like, and blaOXA-
58-like were not determined (Figure 2). Nine pulsotypes
were detected by evaluating all 109 strains with PFGE,
using an ApaI restriction enzyme. In 7 of these pulsotypes,
there were 107 strains (98%) showing similar PFGE
profiles that could not be distinguished from each
other, ranging from 2 to 53. Two of the pulsotypes were
comprised of a strain closely associated with the main
cluster. Given the similarity coefficient as 85% and above,
two major groups were discovered. The first group con-
sisted of 97 strains that are similar to each other at a
92.7% rate, and the second group consisted of 12 strains
that are 100% identical (Figure 3).
During the epidemic, control strategies were determined
with the assistance of an infectious disease specialist,
an infection control nurse, and responsible doctors of
all four ICUs and their nurses. It was separated blood
Figure 1 The distribution of all A.baumannii isolates obtained from in all intensive care units according to months.
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the number of these devices to four: one for surgery
and the CVSICU, one for the MICU, one for the CICU,
and one in emergency services. The devices were blocked
for use and they were made available to health care
workers when absolutely necessary. The second strategy
was placing affected patients in isolated rooms. With very
strict contact measures, all health personnel working in
ICUs were informed one by one of the need for the
prevention of cross-contamination when using their
hands. The importance of controlling hand hygiene and
environmental pollution were highlighted. Disposable
gloves and gowns were provided for all personnel caring
for affected patients, and permission to enter the isolated
rooms was granted to only a few necessary individuals.
The third strategy was the blocking of patient transfersTable 2 The antibiotic sensitivities of A. baumannii isolates an
SAM TZP CAZ FEM AMK GAT
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blaOXA-51-like All isolates (n=109) were positive




SAM: Ampicillin-sulbactam, TZP: Piperacillin-tazobactam, CAZ: Ceftazidime, FEM: Cef
TGC: Tigecycline, CIPX(Ciprofloxacin),CST: Colistin, SXT: Trimethoprim-sulphamethoxbetween the ICUs and exchange of personnel. The fourth
strategy limited environmental pollutions in the ICUs,
as all ICUs were cleaned thoroughly. All surfaces were
completely cleaned with 600 ppm sodium dichloroisocya-
nurate. Isolated rooms also were cleaned last and separately.
The fifth strategy aimed to prevent contamination or pollu-
tion of the environment during endotracheal aspirations by
using a closed aspiration system. A closed aspiration system
was introduced to all patients who required mechanical
ventilation; for those who did require this mechanical aspir-
ation, aseptic open aspiration techniques were followed.
The control measures were followed until two negative
culture results during weekly interval checks were reported.
After patient discharge (or after exitus) from isolated
rooms, the rooms were completely disinfected. After
confirmation of negative environmental culture results,d screening results of OXA genes
































epime, AMK: Amikacin, GAT: Gentamicin, TOB: Tobramicin, NET: Netilmicin.
azole, IPM: Imipenem, MEM: Meropenem.
Figure 2 blaOXA gene profils of A.baumannii strains obtained
from all clinical and environmental samples.
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such as carbapenem, which require a unique, restrictive,
computerized prescription system that can only be accessed
with approval of an infectious disease specialist. During the
epidemic, this antibiotic policy was maintained.
From January 2011 onward, the number of new diag-
nosed cases increased. Although environmental cleaning
and preventive measurements were conducted every
month, pre- and post-cleaning strains were persistent. In
January 2012, the number of new cases peaked, and in
the following two months, the new epidemic control
measures began to take hold and the number of cases
started to decrease. No units were closed. After May,
only one new case, requiring colonization, was detected
in a health care worker.
Discussion
AB is an infectious species that causes severely progressive
infections, and some of its isolates are resistant to most
of antibiotics [25]. Although it is already resistant to
multiple types of antibiotics, including aminoglycosides
and fluoroquinolones, there has been an increase in
recent years in the rates of carbapenem (potent anti-
biotic)-resistant AB strains. Carbapenem-hydrolyzing β-
lactamases (carbapenemase) and molecular D class (OXA
type enzymes) have been found responsible for the basic
mechanism of resistance [26]. Hospital epidemics caused
by carbapenem-resistant AB (CRAB) have caused concern
throughout the world [27]. In recent years, AB epidemics
due to carbapenem-resistant strains have increased in
ICUs [28,29].
According to Ministry of Health 2012 National Hospital
Infections Surveillance Web reports, antimicrobial resist-
ance rates (percentiles) were as follows: throughout Turkey,
in 315 hospitals with 170 units, the number of carbapenem-
resistant AB was 9,196, the number of resistant strains
was 7,114. The number of CRAB was 3145, the number of
resistant strain was 2627. In our study, all strains were
found to be sensitive to colistine and tigecycline. The
biggest resistance was seen in ciprofloxacin with a 98.2%
rate, followed by piperacillin-tazobactam and cefepime
with a 97.2% rate. Imipenem resistance was 91.9% and
meropenem resistance was 93.5%. It could well be attrib-
utable by the frequent use of empirical antibiotics such as
cephalosporins and quinolones in icusIt could well be stemmed by the use of empirical anti-
biotics such as cephalosporins and quinolones in ICUs.
Compared to the carbapenem resistance rate with other
reported rates in our country, 50% to 75% of the rates
were associated with a lower sample size. Previous studies
have shown that each hospital, and even each nation,
has to develop infectious control strategies against multi-
drug resistant AB using a multidisciplinary approach
[7,30,31]. These strategies, including the use of covered
aspiration systems and appropriate antibiotic use, will
control comprehensive environmental decontaminations
[30-32]. Thus, several studies showed that some epidemics
can be controlled by such measures [30-34], although
extremely persistent strains may be very difficult to con-
trol. This situation requires continuing follow-up [35,36].
In the literature, total genom polymorphism with PFGE
is the most reliable method for assessing the epidemiology
of epidemics, and this is accepted as a “gold standard” for
genotyping [24,30,37,38]. According to the results of this
study, PFGE has enough discriminatory power for clonal
separation in follow-up of both short- and long-term
periods, but strains could well obtain the blaOXA genes
from different strains or microorganisms in time. Thus,
it is imperative that the resistance profiles of strains
must be continuously followed with amplification-based
methods, and these methods should be used to support
the PFGE method in the short term. According to the
PFGE method, the one clone is responsible for Acineto-
bacter epidemics in hospitals.
Our results showed that the same strain has been
responsible for contamination in all the ICUs, stemming
from commonly used equipment that was contaminated
by workers. An evaluation of contamination sources, using
cultures from patients and environmental samples, has
indicated that the epidemic might stem from commonly
used blood gas analysis devices. Working personnel could
well be responsible for the environmental contamination
and the resulting cross-contamination. Seen retrospect-
ively, the persistence over a period of months of the
same strain in four different ICUs raised doubts about
the contamination source. Infection control strategies,
such as decreasing environmental pollution and using
antibiotics appropriately, were employed while using
equipment and transporting patients and in tactile contact
with health care workers. Although there was AB persist-
ency, a decrease in cases was achieved before reaching an
epidemic level causing units to be shut down.
In conclusion, OXA type beta-lactamases have traveled
swiftly among CRAB strains, consequently bringing car-
bapenem resistance to dangerous levels. These strains
could be stable for a long time, although the disinfection
procedures applied in hospitals could result in a slight
chance that the same clone might cause another epidemic.
In this context, to prevent persistent bacteria from causing
Figure 3 The PFGE profiles of the 109 A. baumannii outbreak isolates.
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and follow-up procedures be conducted on a continuous
basis, and there is a need for more comprehensive mo-
lecular follow-up studies.
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